To Study the Efficacy and Safety of Renessans in Chronic HCV Patients
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Chronic HCV infection is one of the common causes of the chronic liver disease. Approximately
6-10% of the general public is expected to be suffering from this infection. In case that
these patients are not treated at an appropriate time, these patients develop the sequelae of
the chronic liver disease e.g. cirrhosis of liver, Ascites, and Hepatocellular carinoma.
Interferon alpha 2 a or alpha 2b injections and Ribavirin combination is the treatment of
choice for people suffering from Chronic HCV infection and this combination need to be
administered for 6-12 months. Interferons are biological agents and are to be administered
parenterally. Interferons are expensive and are associated with number of minor and major
adverse effects. Ribavirin is also associated with significant adverse effects. These
compounds cannot be considered as one of the ideal forms of the treatment.
In the past, quite a few natural products have been tested to assess their hepatoprotective
activity and possibly anti viral activity as well. These include Vitamin C (Ascorbic acid),
Vitamin E, Zinc, Silymarin, Red beet roots, crushed licorice and etc. etc.
Rationale Iodine , Potassium iodide and Ascorbic acid are natural products used in the
management of Thyroiditis and chronic cutaneous fungal infections. This combination of iodine
compounds along with ascorbic acid is being used for the management of chronic hepatitis B &
C in the central Asian states e.g. Kazakhstan etc.
The investigators have conducted a feasibility study in which oral Iodine Compound
{RENESSANS} was given to patients suffering HCV related Chronic Active Hepatitis and
anti-viral activity and safety has been analyzed. In this study, RENESSANS containing regimen
has been well tolerated by all the patients and has shown some antiviral activity.
In this study the investigators will assess whether the administration of RENESSANS {oral }
improves the antiviral activity in patients receiving standard interferon therapy.